Latest California Healthline Stories
Estudiante universitaria recibe una cuenta de $17,850 por una prueba de orina
Esta historia forma parte de una serie en la que KHN investigará cuentas médicas sorprendentes enviadas por los usuarios.
Listen: Got A Sky-High Bill? Don’t Write The Check.
Have you gotten a medical bill that sounds way too expensive or is just downright confusing? Send it to us. KHN Editor-in-Chief Elisabeth Rosenthal talks with NPR Morning Edition Host Steve Inskeep about the launch of “Bill Of The Month,” KHN and NPR’s new crowdsourced investigation.
‘Bill Of The Month’: A College Student’s $17,850 Drug Test
Kaiser Health News, in collaboration with NPR, kicks off a series that will examine and decode your perplexing medical bills.
Pain Hits After Surgery When A Doctor’s Daughter Is Stunned By $17,850 Urine Test
Elizabeth Moreno got hit with a $17,850 bill from a Texas lab after leaving a urine sample at her doctor’s office.
Big Pharma Greets Hundreds Of Ex-Federal Workers At The ‘Revolving Door’
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
University Under Fire For Off-The-Grid Herpes Vaccine Experiments
Southern Illinois University’s ethics panel launches “full” inquiry into herpes vaccine experiments on human subjects that took place offshore and in the U.S. without proper oversight by one of its professors, who has since died.
Unregulated Herpes Experiments Expose ‘Black Hole’ Of Accountability
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Doing More Harm Than Good? Epidemic of Screening Burdens Nation’s Older Patients
Patients are often aggressively screened for cancer, even if they won’t live long enough to benefit.
Trump’s HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”